THALES
27.10.2021 09:02:11 CEST | Business Wire | Press release
The 2021 Thales Global Cloud Security Study , commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence, reports that 40% of organisations have experienced a cloud-based data breach in the past 12 months. Despite increasing cyber-attacks targeting data in the cloud, the vast majority (83%) of businesses are still failing to encrypt half of the sensitive data they store in the cloud, raising even greater concerns as to the impact cyber criminals can have.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005044/en/
Pandemic has accelerated cloud transformation
Cloud adoption is on the rise and businesses are continuing to diversify the way they use cloud solutions. Globally, 57% of respondents reported they make use of two or more cloud infrastructure providers, whilst almost a quarter (24%) of organisations flagged that the majority of their workloads and data now reside in the cloud. In fact, according to a recent study by McKinsey & Company, companies globally have accelerated their cloud adoption by three years compared to pre-pandemic adoption rates. This marks a significant shift in the use of cloud-based solutions, from being purely data storage solutions, to environments in which data is used transactionally and supports day-to-day business operations.
Security in the cloud is mixed
According to the study, one fifth (21%) of businesses host the majority of their sensitive data in the cloud, while 40% reported a breach in the last year. There are some common trends as to where companies turn when considering how to secure their cloud infrastructure, with 33% reporting multi-factor authentication (MFA) as being a central part of their cybersecurity strategy. However, only 17% of those surveyed have encrypted more than half of the data they store in the cloud. This figure drops to 15% where organisations have adopted a multicloud approach.
Even where businesses protect their data with encryption, 34% of organisations leave the control of keys to service providers rather than retaining control themselves. Where large numbers of organisations fail to protect their data sufficiently with encryption, limiting potential access points becomes even more critical. However, nearly half (48%) of business leaders globally admitted their organisation does not have a Zero Trust strategy, and a quarter (25%) aren’t even considering one.
Complexity as a concern
Businesses share common concerns about the increasing complexity of cloud services. Almost half (46%) of global respondents claimed managing privacy and data protection in the cloud is more complex than on-premises solutions.
Hybrid models are common with many organisations not moving entirely to the cloud. 55% of businesses have indicated a preference for a ‘lift & shift’ approach to cloud adoption over re-architecting, as cloud becomes a more integrated part of the business infrastructure.
Sebastien Cano, Senior Vice President for Cloud Protection and Licensing activities at Thales comments: “Organisations across the world are struggling to navigate the increased complexity that comes with greater adoption of cloud-based solutions. A robust security strategy is essential to ensuring data and business operations remain secure. With nearly every business reliant on the cloud to some extent, it is vital that security teams have the ability to discover, protect, and maintain control of their data.”
Fernando Montenegro Principal Research Analyst, Information Security at 451 Research, part of S&P Global Market Intelligence added from the 2021 Thales Global Cloud Security Study: “Protecting customer data is always the priority, and organisations should strongly consider reviewing their strategies and approaches to proactively protect data in cloud. This includes understanding the role of specific technologies including encryption and key management, as well as the shared responsibilities between providers and their customers. As data privacy and sovereignty regulations grow, it will be paramount that organisations have a clear understanding of how they remain responsible for data security and make clear decisions about who is in control and who can access their sensitive data.”
Thales and 451 Research will discuss the global findings in more detail during its upcoming Cloud Security Summit on 17 November 2021. To join, please visit the registration page .
About the 2021 Thales Global Cloud Security Study
The 2021 Thales Cloud Security Study was commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence and includes the viewpoints from more than 2,600 executives with responsibility for or influence over IT and data security. Respondents were from 16 countries/regions: Australia, Brazil, France, Germany, Hong Kong, India, Japan, Mexico, Netherlands, New Zealand, Singapore, South Korea, Sweden, the United Arab Emirates, the United Kingdom, and the United States. Organisations represented a range of industries, with a primary emphasis on healthcare, financial services, retail, technology, and federal government. Job titles ranged from C-level executives including CEO, CFO, Chief Data Officer, CISO, Chief Data Scientist, and Chief Risk Officer, to SVP/VP, IT Administrator, Security Analyst, Security Engineer, and Systems Administrator. Respondents represented a broad range of organizational sizes, with the majority ranging from 500 to 10,000 employees. The survey was conducted in January - February 2021.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
